Drugs / anito-cel
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06626919 | Apr 2025 → Mar 2027 expected | myasthenia gravis, myopathy, neuromuscular disease | Arcellx, Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anito-cel | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06626919 ↗ |
| Modality | Cell therapy | “Anitocabtagene autoleucel (anito-cel) is a BCMA-directed CAR-T cell therapy.” NCT06626919 ↗ |
| Route | Intravenous | “Single dose of anito-cel cells infused intravenously” NCT06626919 ↗ |